ADVB
Advanced Biomed Inc. Common Stock
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$9.34
−0.69%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +37.7%
- EBIT
- +51.7%
- EPS
- —
- Free cash flow
- +85.6%
- Operating cash flow
- +85.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +96.1%
- EBIT
- +96.3%
- Net income
- +96.4%
- EPS
- -16.1%
- Free cash flow
- +91.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026